EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients

Daniel Brazeau iD, Kristopher Attwood iD, Louse M Cooper iD, Vanessa Gray, Shirley Chang iD, Shirley Chen, Brian M Murray iD, Kathleen M Tornatore iD

Clinical and Translational Science · 2025-10 · 18 (10)

DOI: 10.1111/cts.70370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 13.10.2025. Verfasst von Daniel Brazeau und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy; Marshall University, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Immunosuppressive Agents, Kidney Transplantation, Tacrolimus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, KMT-PI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interpatient variability in tacrolimus pharmacokinetics is due in part to variation in metabolism by cytochrome P‐450 3A5 and 3A4 and membrane transport by P‐glycoprotein. We evaluated the combined role CYP3A5*3 and CYP3A4*1B genotypes have on tacrolimus pharmacokinetics in 65 stable Black and White kidney transplant recipients receiving maintenance immunosuppression of tacrolimus and mycophenolic acid. Tacrolimus apparent clearance, trough (C 12h ), C 12h /Dose, AUC 0–12 , and AUC 0–12 /Dose as well as CYP3A5 *3 (rs776746) variants responsible for loss of protein function and CYP3A4‐1B ( rs2740574 ) associated with increased CYP3A4 function were assessed. To investigate the association of tacrolimus pharmacokinetics with the CYP3A5 *3 and CYP3A4*1B genotypes, we created a metabolic composite to classify patients as Extensive, Intermediate, and Poor Metabolizers on the basis of the relative expression of specific combinations of CYP3A5 *3 and CYP3A4*1B genotypes. The incorporation of CYP3A5*3 and CYP3A4*1B genotypes that investigate the role of these composite genotypic variants on tacrolimus pharmacokinetics provides additional insights into targeted tacrolimus dosing regimens in these sub‐populations. The Extensive Metabolic Composite had twice the dose and toughs when compared to the Poor composite. Approximately 88% of Blacks were classified as Extensive or Intermediate Metabolizers requiring higher tacrolimus doses to accommodate the more rapid clearance. The remaining Blacks exhibited loss of function SNPs associated with lower tacrolimus doses comparable to Whites. This is the first report describing the association of CYP3A5*3 and CYP3A4‐1B Metabolic Composites on tacrolimus pharmacokinetics in Black and White kidney transplant recipients and provides insight into the interpatient pharmacokinetic variability of this key immunosuppressive drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3AImmunosuppressive AgentsKidney TransplantationTacrolimusAdultAgedFemaleHumansMaleMiddle AgedBlack or African AmericanGenotypeGraft RejectionPolymorphism, Single NucleotideTransplant RecipientsWhite

Stichwörter der Autor:innen

CYP3A4 genotypesCYP3A5 genotypesimmunosuppressionkidney transplantationpharmacogenomicstacrolimus pharmacokinetics

Substanzen

CYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy; Marshall University, USA.
  • Biostatistics, School of Public Health and Health Professions, Buffalo, New York, USA.
  • Immunosuppressive Pharmacology Research Program, Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
  • Nephrology Division; Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.

ORCID-Profile: Daniel Brazeau, Kristopher Attwood, Louse M Cooper, Shirley Chang, Brian M Murray, Kathleen M Tornatore

Förderung

  • NIA NIH HHS
  • KMT-PI

Zitieren

APA

Brazeau, D., Attwood, K., Cooper, L. M., Gray, V., Chang, S., Chen, S., Murray, B. M., & Tornatore, K. M. (2025). Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients. Clinical and Translational Science, 18(10). https://doi.org/10.1111/cts.70370

Vancouver

Brazeau D, Attwood K, Cooper LM, Gray V, Chang S, Chen S, et al. Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients. Clinical and Translational Science. 2025;18(10). doi:10.1111/cts.70370

BibTeX
@article{Brazeau2025,
  author = {Brazeau, Daniel and Attwood, Kristopher and Cooper, Louse M and Gray, Vanessa and Chang, Shirley and Chen, Shirley and Murray, Brian M and Tornatore, Kathleen M},
  title = {Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {10},
  doi = {10.1111/cts.70370}
}
Kostenlos starten →